ArticleTranslational andrology and urology2025
Zhenyuan, a kidney- and spleen-tonifying Chinese medicine compound granule, improves erectile dysfunction and fatigue in orchiectomized rats.
Article in Translational andrology and urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The kidney and spleen are associated with erectile dysfunction (ED) in traditional Chinese medicine (TCM) understanding. Zhenyuan granule (ZYKL) is a Chinese herbal formula with the function of tonifying kidney and spleen and promoting blood circulation. This study aims to evaluate the effects of ZYKL on improving ED and fatigue. Methods: A rat model of orchiectomy (ORX) was developed by removing bilateral testicles. Male Sprague-Dawley rats were divided into Sham, ORX, testosterone (T) propionate (2 mg/kg), ZYKL low-dose (0.94 g/kg), ZYKL middle-dose (3.76 g/kg), and ZYKL high-dose (7.52 g/kg) group. Rats in ZYKL groups were given ZYKL by gavage for 21 days. Sexual behavior parameters, including erection latency (EL), mount latency (ML), and mount frequency (MF), as well as T levels, histological morphology of the penis, and nitric oxide synthase (NOS)-nitric oxide (NO)-cyclic guanosine monophosphate (cGMP) signaling pathway were analyzed to assess sexual function. The weight-loaded forced swimming (WLFS) test was conducted, and the concentrations of blood lactic acid (BLA) and blood urea nitrogen (BUN) were measured to evaluate the anti-fatigue effects. Results: ZYKL significantly elevated T levels, shortened EL and ML, and increased MF in orchiectomized rats, and ameliorated the pathological alterations of the penis induced by ORX. In addition, ZYKL significantly increases NOS activity, NO and cGMP concentrations. Lower BLA and BUN levels were observed in the ZYKL-treated groups after swimming. Conclusions: These results indicate that ZYKL ameliorates ED and fatigue. The mechanism for improving ED might be associated with activating the NOS-NO-cGMP signaling pathway and elevating T levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.